Preliminary Analysis Demonstrates CSS Device Has To Date Exceeded Expectations for Specificity and Sensitivity Compared to Duplex Doppler Ultrasound
VANCOUVER, BC / August 20th, 2018 / CVR Medical Corp. (CVM.V) (TSXV: CVM) (OTCQB: CRRVF) (“CVR Medical”) a Canadian listed and US based healthcare company in the medical device sector announces advisory staff member Dr. Phillip J. Bendick, PhD, has released an internal report summarizing data from the pivotal clinical trials for the Carotid Stenotic Scan (CSS) devices in use at Thomas Jefferson University Hospital. In alignment with the previous report released by Dr. Bendick in September 2017, this preliminary report views the initial batch of data points collected within the trial as successful for the substantiation of the device’s value and efficacy. Though only a partial snapshot of the data (with the trial ongoing), the improvements made to the CSS prior to launch of the pivotal clinical trials has generated enhanced functionality within the clinical setting.
The CSS Device is being evaluated in a multi-center pivotal clinical trial to evaluate the system’s specificity and sensitivity for detecting carotid artery disease, compared to the current gold standard – duplex Doppler ultrasound.
Dr. Bendick states, “The early results of the first 144 patients enrolled in the CSS pivotal trial have shown excellent overall accuracy […] these initial results demonstrate the efficacy of the CSS as a tool to detect and guide the appropriate management of clinically important carotid artery disease in order to reduce stroke risk.”
“This report further validates the advancements implemented by CVR prior to the launch of our pivotal trials,” said Peter Bakema, CVR CEO. “All along we have aimed to arm the clinician with a tool that is not only accurate, but seamlessly translates to improved care for his or her patients. Every aspect of the CSS, from the user interface to the streamlined cart, embodies this principle. This preliminary report reinforces our previously stated commitment to deliver a product with greater than 85% sensitivity level.”
Additionally, due to the current extended lead time for mandatory electrical safety testing, CVR has extended its anticipated CSS FDA submission target to October 2018.
Carotid Stenotic Scan Pivotal Trial Internal Data Analysis: Data Summary with Patient Edits* By: Phillip J. Bendick, PhD
Location: Thomas Jefferson University Hospital
Primary Investigator: Dr. David Whellan
Number of Samples Evaluated (Vessels): N=255**
True Negative (<50%)
True Positive (>50%)
False Positive / Negative Causes
|Incorrect Sensor Array Placement||4|
|Excessive Noise (Internal)||2|
Given These Results-
* Patient exclusions (33 vessels): Prior carotid endarterectomy, prior carotid stent, prior neck surgery, severe heart disease.
** Vessels with No Reading (NR) or poor Quality of Placement (QOP) – 38 (Most of these were on Device 7)
CAUTION: FOR INVESTIGATIONAL USE ONLY. This device is not yet cleared or approved for use in humans by the Food and Drug Administration.
About CVR Medical
CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary CSS Device. The CSS device is a diagnostic tool that encompasses subsonic, infrasonic, and low frequency sound wave analysis technology. The CSS Device is a patented device designed to detect and measure carotid arterial stenosis. CVR is currently in pivotal clinical trials in preparation for its planned submission to the FDA. CVR is led by an experienced and proven team of professionals with extensive healthcare, medical device, international expansion, regulatory and sales experience. CVR Medical trades on the TSX Venture Exchange under the symbol CVM. Additional information regarding the Company can be found in our recent filings with the SEDAR as well as the information maintained on our website at www.cvrmed.com
For further information contact:
Peter Bakema, CEO, President and Director
Telephone: (734) 718-5115
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888
Marc S. Lubow.
Vice President Capital Markets, Investor Relations
Telephone: (904) 923 – 4037
This press release contains forward-looking statements or information (collectively referred to herein as “forward-looking statements”) that involves various risks and uncertainties regarding future events related to the Joint Venture and the Transaction. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. In this press release such statements include but are not limited to the completion of the Transaction and the associated regulatory and shareholder approval requirements. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company’s control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.